Alzamend Neuro Files 8-K on Shareholder Votes and Financials
Ticker: ALZN · Form: 8-K · Filed: Jul 8, 2024 · CIK: 1677077
| Field | Detail |
|---|---|
| Company | Alzamend Neuro, INC. (ALZN) |
| Form Type | 8-K |
| Filed Date | Jul 8, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $25,000,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, financials, filing
TL;DR
Alzamend Neuro filed an 8-K on July 8th covering shareholder votes and financials.
AI Summary
Alzamend Neuro, Inc. filed an 8-K on July 8, 2024, reporting on matters submitted to a vote of security holders and including financial statements and exhibits. The company, incorporated in Delaware, is in the pharmaceutical preparations industry and is headquartered in Atlanta, GA.
Why It Matters
This filing provides updates on corporate governance and financial status, which are crucial for investors to assess the company's operational and financial health.
Risk Assessment
Risk Level: low — This is a routine filing of corporate information and does not indicate any immediate material changes or risks.
Key Numbers
- 001-40483 — SEC File Number (Identifies the company's filing history with the SEC.)
- 81-1822909 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Alzamend Neuro, Inc. (company) — Registrant
- July 8, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Atlanta, GA (location) — Principal executive offices
FAQ
What specific matters were submitted to a vote of security holders?
The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in the excerpt.
What type of financial statements are included in this filing?
The filing states that 'Financial Statements and Exhibits' are included, but the specific nature or period of these statements is not detailed in the provided text.
When was Alzamend Neuro, Inc. incorporated?
Alzamend Neuro, Inc. was incorporated in Delaware, as stated in the filing.
What is the principal business address of Alzamend Neuro, Inc.?
The principal executive offices are located at 3480 Peachtree Road NE, Second Floor, Suite 103, Atlanta, GA 30326.
What is the SIC code for Alzamend Neuro, Inc.?
The Standard Industrial Classification (SIC) code for Alzamend Neuro, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 707 words · 3 min read · ~2 pages · Grade level 10.7 · Accepted 2024-07-08 16:30:20
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value ALZN The Nasdaq Capital M
- $25,000,000 — ck, for a total purchase price of up to $25,000,000.00, issued pursuant to the Securities P
Filing Documents
- o782458k.htm (8-K) — 26KB
- 0001214659-24-012079.txt ( ) — 199KB
- alzn-20240708.xsd (EX-101.SCH) — 3KB
- alzn-20240708_lab.xml (EX-101.LAB) — 33KB
- alzn-20240708_pre.xml (EX-101.PRE) — 22KB
- o782458k_htm.xml (XML) — 4KB
07
Item 5.07 Submission of Matters to a Vote of Security Holders. On July 8, 2024, Alzamend Neuro, Inc., a Delaware corporation (the " Company ") held a Special Meeting of Stockholders (the " Meeting "). As of May 29, 2024, the record date for the Special Meeting, the voting power of the Company consisted of (i) 7,376,011 shares of common stock, par value $0.0001 per share (the " Common Stock ") issued and outstanding, (ii) 78.8236 shares of Series A convertible preferred stock (the " Series A Preferred Stock "), which as of the record date were entitled to cast votes equal to 1,375,310 shares of Common Stock and (iii) 2,100 shares of the Series B Convertible Preferred Stock, which as of the record date were convertible into 2,100,000 shares of Common Stock, which together constitute all of the outstanding voting capital stock of the Company. At the Meeting, the stockholders voted on one proposal, which is described in more detail in the Company's definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on May 31, 2024, as supplemented on June 11, 2024. At the Meeting, stockholders approved the proposal presented for a vote. The table below sets forth the number of votes cast for and against or withheld, and the number of abstentions or broker non-votes, for the matter voted upon by the Company's stockholders. Proposal One : Approval of, pursuant to Rule 5635 of the Nasdaq Stock Market, the conversion of the Company's shares of Series A Preferred Stock into shares of Common Stock, and warrants to purchase shares of Common Stock, for a total purchase price of up to $25,000,000.00, issued pursuant to the Securities Purchase Agreement dated May 8, 2024 and the Certificate of Designations of the Rights and Preferences of Series A Preferred Stock. For Against Abstain Broker Non-Votes 5,356,845 79,371 3,043 0
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 101 Pursuant to Rule 406 of Regulation S-T, the cover page is formatted in Inline XBRL (Inline eXtensible Business Reporting Language). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101). -2- SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALZAMEND NEURO, INC. Dated: July 8, 2024 /s/ David J. Katzoff David J. Katzoff Chief Financial Officer -3-